Simris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1835 SEK | -5.90% | +7.00% | -18.44% |
May. 27 | Simris Group AB Announces Robert Quandt Declines Re-Election as Member of Board | CI |
May. 15 | Simris Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-18.44% | 6.06M | |
+9.79% | 7.89B | |
+2.60% | 7.2B | |
-2.68% | 5.75B | |
-8.03% | 3.64B | |
-14.39% | 3.42B | |
-15.43% | 1.16B | |
-28.11% | 1.1B | |
+5.08% | 906M | |
-13.46% | 828M |
- Stock Market
- Equities
- SIMRIS B Stock
- News Simris Group AB
- Simris Group AB Confirms New Patent Application from Its Adc-Payload Platform